Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company discovers, develops ... as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations ... same website for approximately 30 days. The company currently plans to share its full Q4 2024 ...

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4 2024 revenue is expected to be ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines ... immunology to neuroscience. Eli Lilly and Company (NYSE: LLY) will announce ...